Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Statement on a nonproprietary name adopted by the USAN Council
A gender gap in autoimmunity.
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Teriflunomide for multiple sclerosis.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Merck: Regulatory Update on Cladribine Tablets
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
β-Amyloid: Enemy or Remedy?
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Visualization of myelination in GFP-transgenic zebrafish.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?

Pages